Johnson & Johnson is expecting that sales of its COVID-19 vaccines could rise to $3.5 billion in 2022, though the total will not account for much of its overall profits.
J&J expects COVID-19 vaccine sales boost in 2022 on strong demand
© The Crystal Eyes